Rafiq and colleagues describe the retained ectodomain of Muc16, Muc16CD, as a novel TAA for targeting by chimeric antigen receptor (CAR) T cell therapy in pancreatic cancer. This evidence concerns the gene MUC16 and familial pancreatic carcinoma.